

The Development of a Comprehensive Archive of Patient-Reported Outcome Measures (PROMS) for Clinical Research and Clinical Practice in Oncology

Malandrini F¹, Meregaglia M¹, Pinto C², Di Maio M³, Ciani O¹

¹ Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Milan, Italy; ² Department of Medical Oncology, S. Maria Hospital - IRCCS, Reggio Emilia, Italy; ³ University of Turin, Torino, TO, Italy

BACKGROUND

- ❑ Patient-reported outcomes (PROs) are health or treatment outcomes reported **directly by the patient** without added interpretation of a healthcare professional or anyone else [1].
- ❑ PROs chosen in suitable and accurate manners can help to identify symptoms that might benefit from supportive interventions, determine the recovery time needed to return to usual activities, and prepare **future cancer patients** for what to expect during and after treatment.
- ❑ The advantage of using PROs in clinical practice and research is that they provide a more comprehensive interpretation of the benefits of the intervention delivered or under investigation. However, **choosing the most adequate measure of PROs** in clinical trials, clinical practice, and post-authorization studies is not straightforward [2].

RESEARCH OBJECTIVES

- ❑ Identifying the **different measures** that exist in **oncology** and classifying them according to their characteristics and properties is the first step in getting a clear picture of the **instruments available** to measure the quality of life of cancer patients.
- ❑ This study aims to develop a comprehensive **archive of patient-reported outcome measures (PROMs)** in oncology and identify their main characteristics and target outcome domains.


METHODS

As part of the **PRO4All project**, we retrieved the available PROMs in **oncology** by searching websites (e.g., facit.org, eortc.org, eprovide.mapi-trust.org), ema.europa.eu (European Public Assessment Reports), and published reviews. We developed a data extraction form to collect information on: PROM name, cancer area (based on ICD-10), type of questionnaire (i.e., self-reported, proxy-reported or caregiver's report), questionnaire variant(s), recall period (e.g., last week), validation and MCID (Minimal Clinically Important Difference) studies, number of items and types of scoring. Moreover, we assigned **each item** a **specific domain** according to a predefined 38-item taxonomy for outcome classification [3].


RESULTS

A total of **340 PROMs** were identified and fully analyzed. Over half (n=166, **48.8%**) were cancer type-specific, 150 (**44.1%**) were generic for cancer and 24 (**7.1%**) were intended for the general population but also recommended or used for cancer patients. Half of the instruments (**50.3%**) indicated 'last week' as recall period. In the great majority of cases (**94%**), the questionnaire was self-reported and in the remaining **6%** reported by proxy (e.g., caregiver, parent) or focused on caregiver's health or situation. Besides original questionnaires (**83%**), we identified **52** variants (e.g., short versions, parental versions) and **11** duplicates (i.e., same items). The mean number of items per questionnaire was **22.1** (range: 1- 130). In total, **7527** items were assigned an outcome domain, which was emotional functioning/wellbeing in **21.1%** of cases, physical functioning/wellbeing in **16.3%** and general outcomes in **10.1%**.


Types of Cancer (N = 340)



Outcome domains (N = 7527)




Reporting




■ Self-reported
■ Proxy-reported
■ Reported by caregiver on his/her health

Types of questionnaires




■ Original
■ Variant
■ Duplicate

Scoring



■ Total score
■ Total and sub scores
■ Subscores
■ Unknown

Recall period



■ Last week
■ NS
■ Last month
■ Today
■ Treatment related
■ Other

DISCUSSION

This review study highlighted a significant number and heterogeneity of PROMs in oncology, even within the same cancer area. The newly developed archive represents a useful tool for guiding researchers and practitioners in selecting the most suitable measures for cancer patients and fostering a patient-centered approach in oncology.

REFERENCES

[1] Meregaglia, M. et al., The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy (2023); [2] M. Di Maio et al., on behalf of the ESMO Guidelines Committee Annals of Oncology; [3] Dodd S et al., A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018.

ACKNOWLEDGEMENTS: This study was supported by a research grant (PRO4All) from Roche Italy to CERGAS (SDA Bocconi).

PRESENTING AUTHOR: Francesco Malandrini; francesco.malandrini@sdabocconi.it